Combining anti-PD(L)1 antibodies with novel agents engaging different immune and non-immune mechanisms, as well as exploring different settings and stages within the realm of HCC, promises to further improve patient outcomes. This evidence concerns the gene CD274 and hepatocellular carcinoma.